



CORRECTION

# Correction to: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM

Ichiro Nakamura · Hiroshi Maegawa · Kazuyuki Tobe · Satoshi Uno

Published online: August 31, 2021  
© The Author(s) 2021

Correction to: Diabetes Ther (2021) 12:1359–1378  
<https://doi.org/10.1007/s13300-021-01042-w>

In the original article, ADR data from STELLA-ELDER are provided for Table 3 incorrectly which is originally for Table 2.

## RESULTS

### Safety

#### Original

ADR data from STELLA-ELDER are provided in Table 3 for comparison [9].

#### Corrected

ADR data from STELLA-ELDER are provided in Table 2 for comparison [9].

In the original article, Table S1 was published with some errors. The correct Table S1 is given below.

---

The original article can be found online at <https://doi.org/10.1007/s13300-021-01042-w>.

---

I. Nakamura (✉)  
Operational Excellence, Medical Affairs Japan,  
Astellas Pharma Inc., Tokyo, Japan  
e-mail: [ichiro.nakamura@astellas.com](mailto:ichiro.nakamura@astellas.com)

H. Maegawa  
Department of Medicine, Shiga University of  
Medical Science, Shiga, Japan

K. Tobe  
First Department of Internal Medicine, Graduate  
School of Medicine and Pharmaceutical Sciences for  
Research, University of Toyama, Toyama, Japan

S. Uno  
Data Science, Development, Astellas Pharma Inc.,  
Tokyo, Japan

<b>Original</b>				
	<b>&lt; 65 years</b>	<b>65– &lt; 75 years</b>	<b>≥ 75 years</b>	<b><i>P</i>-value<sup>a</sup></b>
All, <i>n</i>	7894	2405	752	
Sex, <i>n</i> (%)				
Male	5023 (63.6)	1305 (54.3)	385 (51.2)	(1) < 0.001
Female	2871 (36.4)	1100 (45.7)	367 (48.8)	
Age, years				
Mean ± SD	51.2 ± 9.0	68.7 ± 2.9	79.4 ± 3.9	
Median (range)	52.0 (14–64)	68.0 (65–74)	78.0 (75–95)	
Body weight, kg, mean ± SD ( <i>n</i> )	81.92 ± 17.35 (6015)	68.74 ± 11.89 (1693)	63.27 ± 11.46 (464)	(2) < 0.001
BMI, kg/m <sup>2</sup>				
Mean ± SD ( <i>n</i> )	29.90 ± 5.44 (5548)	26.95 ± 4.06 (1536)	26.02 ± 4.03 (408)	(2) < 0.001
< 25.0, <i>n</i> (%)	883 (11.2)	515 (21.4)	175 (23.3)	(1) < 0.001
≥ 25.0, <i>n</i> (%)	4665 (59.1)	1021 (42.5)	233 (31.0)	
Unknown	2346 (29.7)	869 (36.1)	344 (45.7)	
Duration of diabetes, years				
Mean ± SD ( <i>n</i> )	7.22 ± 5.74 (5417)	9.80 ± 7.34 (1449)	11.51 ± 9.17 (382)	(2) < 0.001
< 5, <i>n</i> (%)	2124 (26.9)	382 (15.9)	87 (11.6)	(1) < 0.001
≥ 5, <i>n</i> (%)	3293 (41.7)	1067 (44.4)	295 (39.2)	
Unknown, <i>n</i> (%)	2477 (31.4)	956 (39.8)	370 (49.2)	
Complications, <i>n</i> (%)				
Yes	6603 (83.6)	279 (11.6)	88 (11.7)	(1) < 0.001
No	1232 (15.6)	2107 (87.6)	655 (87.1)	
Unknown	59 (0.7)	19 (0.8)	9 (1.2)	
eGFR, mean mL/min/1.73 m <sup>2</sup> ± SD ( <i>n</i> )	85.56 ± 19.35 (4762)	72.48 ± 17.23 (1504)	63.85 ± 18.83 (431)	(2) < 0.001
HbA1c, <i>n</i> (%)				
Mean ± SD ( <i>n</i> ) <sup>b</sup>	8.17 ± 1.51 (6413)	7.84 ± 1.25 (1806)	7.56 ± 1.15 (507)	(2) < 0.001
< 8%	3958 (50.1)	1404 (58.4)	473 (62.9)	(1) < 0.001
≥ 8%	3473 (44.0)	803 (33.4)	206 (27.4)	
Unknown	463 (5.9)	198 (8.2)	73 (9.7)	
Initial dose of ipragliflozin, <i>n</i> (%)				

continued

	< 65 years	65– < 75 years	≥ 75 years	<i>P</i> -value <sup>a</sup>
25 mg	879 (11.1)	369 (15.3)	172 (22.9)	– <sup>c</sup>
50 mg	6999 (88.7)	2033 (84.5)	580 (77.1)	
100 mg	13 (0.2)	2 (0.1)	0	
Other	3 (0.04)	1 (0.04)	0	
Daily dose of ipragliflozin, mg, mean ± SD ( <i>n</i> )	48.34 ± 8.39 (7894)	47.27 ± 9.62 (2405)	44.99 ± 10.60 (752)	(2) < 0.001
Dose changes during treatment, <i>n</i> (%)				
25 mg to 25 mg	602 (7.6)	274 (11.4)	145 (19.3)	– <sup>c</sup>
25 mg to 50 mg	242 (3.1)	78 (3.2)	24 (3.2)	
50 mg to 50 mg	6765 (85.7)	1958 (81.4)	556 (73.9)	
50 mg to 100 mg	121 (1.5)	35 (1.5)	6 (0.8)	
Other	164 (2.1)	60 (2.5)	21 (2.8)	

*BMI* body mass index, *eGFR* estimated glomerular filtration rate, *HbA1c* glycated hemoglobin, *SD* standard deviation

<sup>a</sup> *P* values across subgroups assessed by (1) chi-squared test, or (2) one-way analysis of variance; no statistical comparison between groups was made for specific complications

<sup>b</sup> Mean HbA1c values were from the effectiveness analysis set

<sup>c</sup> No *P* value was calculated when at least one element of the contingency table was < 10

<b>Corrected</b>				
	<b>&lt; 65 years</b>	<b>65– &lt; 75 years</b>	<b>≥ 75 years</b>	<b><i>P</i>-value<sup>a</sup></b>
All, <i>n</i>	7894	2405	752	
Sex, <i>n</i> (%)				
Male	5023 (63.6)	1305 (54.3)	385 (51.2)	(1) < 0.001
Female	2871 (36.4)	1100 (45.7)	367 (48.8)	
Age, years				
Mean ± SD	51.2 ± 9.0	68.7 ± 2.9	79.4 ± 3.9	
Median (range)	52.0 (14–64)	68.0 (65–74)	78.0 (75–95)	
Body weight, kg, mean ± SD ( <i>n</i> )	81.92 ± 17.35 (6015)	68.74 ± 11.89 (1693)	63.27 ± 11.46 (464)	(2) < 0.001
BMI, kg/m <sup>2</sup>				
Mean ± SD ( <i>n</i> )	29.90 ± 5.44 (5548)	26.95 ± 4.06 (1536)	26.02 ± 4.03 (408)	(2) < 0.001
< 25.0, <i>n</i> (%)	883 (11.2)	515 (21.4)	175 (23.3)	(1) < 0.001
≥ 25.0, <i>n</i> (%)	4665 (59.1)	1021 (42.5)	233 (31.0)	
Unknown	2346 (29.7)	869 (36.1)	344 (45.7)	
Duration of diabetes, years				
Mean ± SD ( <i>n</i> )	7.22 ± 5.74 (5417)	9.80 ± 7.34 (1449)	11.51 ± 9.17 (382)	(2) < 0.001
< 5, <i>n</i> (%)	2124 (26.9)	382 (15.9)	87 (11.6)	(1) < 0.001
≥ 5, <i>n</i> (%)	3293 (41.7)	1067 (44.4)	295 (39.2)	
Unknown, <i>n</i> (%)	2477 (31.4)	956 (39.8)	370 (49.2)	
Complications, <i>n</i> (%)				
Yes	6603 (83.6)	2107 (87.6)	655 (87.1)	(1) < 0.001
No	1232 (15.6)	279 (11.6)	88 (11.7)	
Unknown	59 (0.7)	19 (0.8)	9 (1.2)	
eGFR, mean mL/min/1.73 m <sup>2</sup> ± SD ( <i>n</i> )	85.56 ± 19.35 (4762)	72.48 ± 17.23 (1504)	63.85 ± 18.83 (431)	(2) < 0.001
HbA1c, <i>n</i> (%)				
Mean ± SD ( <i>n</i> ) <sup>b</sup>	8.17 ± 1.51 (6413)	7.84 ± 1.25 (1806)	7.56 ± 1.15 (507)	(2) < 0.001
< 8%	3958 (50.1)	1404 (58.4)	473 (62.9)	(1) < 0.001
≥ 8%	3473 (44.0)	803 (33.4)	206 (27.4)	
Unknown	463 (5.9)	198 (8.2)	73 (9.7)	
Initial dose of ipragliflozin, <i>n</i> (%)				

continued

	< 65 years	65– < 75 years	≥ 75 years	<i>P</i> -value <sup>a</sup>
25 mg	879 (11.1)	369 (15.3)	172 (22.9)	– <sup>c</sup>
50 mg	6999 (88.7)	2033 (84.5)	580 (77.1)	
100 mg	13 (0.2)	2 (0.1)	0	
Other	3 (0.04)	1 (0.04)	0	
Daily dose of ipragliflozin, mg, mean ± SD ( <i>n</i> )	48.34 ± 8.39 (7894)	47.27 ± 9.62 (2405)	44.99 ± 10.60 (752)	(2) < 0.001
Dose changes during treatment, <i>n</i> (%)				
25 mg to 25 mg	602 (7.6)	274 (11.4)	145 (19.3)	– <sup>c</sup>
25 mg to 50 mg	242 (3.1)	78 (3.2)	24 (3.2)	
50 mg to 50 mg	6765 (85.7)	1958 (81.4)	556 (73.9)	
50 mg to 100 mg	121 (1.5)	35 (1.5)	6 (0.8)	
Other	164 (2.1)	60 (2.5)	21 (2.8)	

*BMI* body mass index, *eGFR* estimated glomerular filtration rate, *HbA1c* glycated hemoglobin, *SD* standard deviation

<sup>a</sup> *P* values across subgroups assessed by (1) chi-squared test, or (2) one-way analysis of variance; no statistical comparison between groups was made for specific complications

<sup>b</sup> Mean HbA1c values were from the effectiveness analysis set

<sup>c</sup> No *P* value was calculated when at least one element of the contingency table was < 10

**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are

included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.